Comparison of clinical variables at initial diagnosis
| . | Clinical case 1 . | Clinical case 2 . |
|---|---|---|
| Hb level | 8.5 g/dL | 7.9 g/dL |
| PLT level | 250 × 109/L | 192 × 109/L |
| ANC count | 2.5 × 109/L | 2.7 × 109/L |
| BM blast count | 3% | 2% |
| Cytogenetic analysis | +19 | +19 |
| Molecular analysis | TET2 (VAF, 35%) | ASXL1 (VAF, 28%) |
| DNMT3A (VAF, 25%) | ETV6 (VAF, 32%) | |
| SF3B1 (VAF, 22%) | U2AF1 (VAF, 22%) | |
| MDS WHO subtype | MDS-RS-SLD | MDS-RS-SLD |
| IPSS | 0.5 (intermediate 1) | 0.5 (intermediate 1) |
| IPSS-R | 4.0 (intermediate) | 3.5 (intermediate) |
| . | Clinical case 1 . | Clinical case 2 . |
|---|---|---|
| Hb level | 8.5 g/dL | 7.9 g/dL |
| PLT level | 250 × 109/L | 192 × 109/L |
| ANC count | 2.5 × 109/L | 2.7 × 109/L |
| BM blast count | 3% | 2% |
| Cytogenetic analysis | +19 | +19 |
| Molecular analysis | TET2 (VAF, 35%) | ASXL1 (VAF, 28%) |
| DNMT3A (VAF, 25%) | ETV6 (VAF, 32%) | |
| SF3B1 (VAF, 22%) | U2AF1 (VAF, 22%) | |
| MDS WHO subtype | MDS-RS-SLD | MDS-RS-SLD |
| IPSS | 0.5 (intermediate 1) | 0.5 (intermediate 1) |
| IPSS-R | 4.0 (intermediate) | 3.5 (intermediate) |
ANC, absolute neutrophil count; BM, bone marrow; Hb, hemoglobin; PLT, platelet.